147 related articles for article (PubMed ID: 7620184)
1. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.
Ohnishi K; Ohno R; Tomonaga M; Kamada N; Onozawa K; Kuramoto A; Dohy H; Mizoguchi H; Miyawaki S; Tsubaki K
Blood; 1995 Aug; 86(3):906-16. PubMed ID: 7620184
[TBL] [Abstract][Full Text] [Related]
2. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
3. A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group.
Ohnishi K; Tomonaga M; Kamada N; Onozawa K; Kuramoto A; Dohy H; Mizoguchi H; Miyawaki S; Tsubaki K; Miura Y; Omine M; Kobayashi T; Naoe T; Ohshima T; Hirashima K; Ohtake S; Takahashi I; Morishima Y; Naito K; Asou N; Tanimoto M; Sakuma A; Ohno R
Leuk Res; 1998 Sep; 22(9):779-86. PubMed ID: 9716008
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
[TBL] [Abstract][Full Text] [Related]
5. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
[TBL] [Abstract][Full Text] [Related]
6. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
[TBL] [Abstract][Full Text] [Related]
7. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
[TBL] [Abstract][Full Text] [Related]
8. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
Itoh T; Tamura S; Takemoto Y; Kakishita E
Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
[TBL] [Abstract][Full Text] [Related]
9. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
Talpaz M; Kantarjian H; Kurzrock R; Trujillo JM; Gutterman JU
Ann Intern Med; 1991 Apr; 114(7):532-8. PubMed ID: 2001086
[TBL] [Abstract][Full Text] [Related]
11. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
Maloisel F; Uettwiller F; Laplace A; Lioure B; Herbrecht R; Mark M; Dufour P
Cancer Genet Cytogenet; 1999 Sep; 113(2):172-6. PubMed ID: 10484986
[TBL] [Abstract][Full Text] [Related]
12. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
[TBL] [Abstract][Full Text] [Related]
13. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
17. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
[TBL] [Abstract][Full Text] [Related]
18. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha].
Hong H; Qiu JY; Lai YY; Shi Y; He Q; Dang H; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):269-73. PubMed ID: 12844411
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
Leukemia; 1998 Jun; 12(6):860-4. PubMed ID: 9639411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
